Zactima Gets Fast Track Status for Medullary Thyroid Cancer

Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

AstraZeneca, Zactima, ZD6474, medullary thyroid cancer

WILMINGTON, Delaware—AstraZeneca's Zactima (ZD6474) has received FDA fast track designation for the treatment of medullary thyroid cancer. Zactima, a once-daily oral agent, targets tumor cells through inhibition of EGFR and REarranged during Transfection (RET) tyrosine kinases, and tumor blood supply through inhibition of VEGFR tyrosine kinase. Zactima, which also has orphan drug status for medullary thyroid cancer, is currently being evaluated in a phase II clinical trial.

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Related Content